Results	O
for	O
patients	O
with	O
sarcoma	B:C1261473
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
Euro	O
-	I:C0008976
EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
.	O

Results	O
for	O
patients	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	B:C0011900
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
Euro	O
-	I:C0008976
EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
.	O

Results	O
for	O
patients	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	O
than	O
Ewing	B:C0553580
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
Euro	O
-	I:C0008976
EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
.	O

Results	O
for	O
patients	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	B:C0332154
according	O
to	O
the	O
Euro	O
-	I:C0008976
EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
.	O

Results	O
for	O
patients	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
Euro	B:C0008976
-	I:C0008976
EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
.	O

Euro	B:C0008976
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	O
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	B:C1535514
Ewing	O
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	B:C0553580
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	O
tumor	I:C0553580
Working	O
Initiative	B:C1287154
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	O
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	B:C0015737
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	O
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	O
Groups	O
(	O
EE99	B:C1507394
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	O
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	B:C0282461
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	O
sarcoma	I:C0553580
.	O

Euro	O
-EWING	I:C0008976
99	I:C0008976
trial	I:C0008976
of	O
the	O
European	O
Ewing	O
tumor	I:C0553580
Working	O
Initiative	O
of	O
National	O
Groups	O
(	O
EE99	O
)	O
was	O
an	O
international	O
phase	O
III	I:C0282461
study	I:C0282461
in	O
patients	O
with	O
Ewing	B:C0553580
sarcoma	I:C0553580
.	O

The	O
German	B:C1708333
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	O
and	O
followed	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
who	O
were	O
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	O
database	I:C0242356
.	O

The	O
German	O
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	B:C1514821
and	O
followed	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
who	O
were	O
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	O
database	I:C0242356
.	O

The	O
German	O
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	O
and	O
followed	O
patients	O
with	O
other	O
diagnoses	B:C0011900
than	O
Ewing	O
sarcoma	I:C0553580
who	O
were	O
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	O
database	I:C0242356
.	O

The	O
German	O
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	O
and	O
followed	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	B:C0553580
sarcoma	I:C0553580
who	O
were	O
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	O
database	I:C0242356
.	O

The	O
German	O
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	O
and	O
followed	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
who	O
were	O
treated	B:C0332154
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	O
database	I:C0242356
.	O

The	O
German	O
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	O
and	O
followed	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
who	O
were	O
treated	O
according	O
to	O
the	O
EE99	B:C1507394
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	O
database	I:C0242356
.	O

The	O
German	O
Society	I:C1708333
of	I:C1708333
Pediatric	I:C1708333
Oncology	I:C1708333
and	I:C1708333
Hematology	I:C1708333
(	I:C1708333
GPOH	I:C1708333
)	I:C1708333
data	I:C1708333
center	I:C1708333
registered	O
and	O
followed	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
who	O
were	O
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
in	O
an	O
additional	O
non-Ewing	B:C0242356
database	I:C0242356
.	O

Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	B:C0011900
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
were	O
analyzed	O
.	O

Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	B:C0553580
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
were	O
analyzed	O
.	O

Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	B:C0332154
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
were	O
analyzed	O
.	O

Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
EE99	B:C1507394
protocol	I:C1507394
were	O
analyzed	O
.	O

Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
the	O
EE99	O
protocol	I:C1507394
were	O
analyzed	B:C0936012
.	O

Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	B:C0011900
,	O
the	O
majority	O
were	O
diagnosed	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	O
and	O
soft	O
tissue	I:C0225317
(	O
63	O
%	O
)	O
.	O

Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	O
,	O
the	O
majority	O
were	O
diagnosed	B:C0011900
with	O
sarcoma	O
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	O
and	O
soft	O
tissue	I:C0225317
(	O
63	O
%	O
)	O
.	O

Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	O
,	O
the	O
majority	O
were	O
diagnosed	O
with	O
sarcoma	B:C1261473
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	O
and	O
soft	O
tissue	I:C0225317
(	O
63	O
%	O
)	O
.	O

Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	O
,	O
the	O
majority	O
were	O
diagnosed	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	B:C0391978
and	O
soft	O
tissue	I:C0225317
(	O
63	O
%	O
)	O
.	O

Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	O
,	O
the	O
majority	O
were	O
diagnosed	O
with	O
sarcoma	O
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	O
and	O
soft	B:C0225317
tissue	I:C0225317
(	O
63	O
%	O
)	O
.	O

The	O
median	O
age	O
at	O
diagnosis	B:C0011900
was	O
16.9	O
years	O
(	O
range	O
4.5-41.4	O
)	O
.	O

Localized	B:C0277565
disease	I:C0277565
was	O
diagnosed	O
in	O
61.5	O
%	O
of	O
the	O
patients	O
and	O
38.5	O
%	O
had	O
distant	O
metastases	I:C0027627
at	O
time	O
of	O
primary	O
diagnosis	O
.	O

Localized	O
disease	I:C0277565
was	O
diagnosed	B:C0011900
in	O
61.5	O
%	O
of	O
the	O
patients	O
and	O
38.5	O
%	O
had	O
distant	O
metastases	I:C0027627
at	O
time	O
of	O
primary	O
diagnosis	O
.	O

Localized	O
disease	I:C0277565
was	O
diagnosed	O
in	O
61.5	O
%	O
of	O
the	O
patients	O
and	O
38.5	O
%	O
had	O
distant	B:C0027627
metastases	I:C0027627
at	O
time	O
of	O
primary	O
diagnosis	O
.	O

Localized	O
disease	I:C0277565
was	O
diagnosed	O
in	O
61.5	O
%	O
of	O
the	O
patients	O
and	O
38.5	O
%	O
had	O
distant	O
metastases	I:C0027627
at	O
time	O
of	O
primary	O
diagnosis	B:C0011900
.	O

The	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
time	O
was	O
3.7	O
years	O
(	O
range	O
0.5-9.5	O
)	O
.	O

Patients	O
with	O
localized	B:C0277565
disease	I:C0277565
showed	O
a	O
3	O
-	O
year	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
of	O
68	O
%	O
,	O
compared	O
to	O
3	O
-	O
year	O
EFS	O
of	O
20	O
%	O
in	O
patients	O
with	O
metastases	O
(	O
P	O
=	O
0.042	O
)	O
.	O

Patients	O
with	O
localized	O
disease	I:C0277565
showed	O
a	O
3	O
-	O
year	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
of	O
68	O
%	O
,	O
compared	O
to	O
3	O
-	O
year	O
EFS	O
of	O
20	O
%	O
in	O
patients	O
with	O
metastases	B:C0027627
(	O
P	O
=	O
0.042	O
)	O
.	O

Three	O
-	O
year	O
EFS	O
for	O
patients	O
with	O
sarcoma	B:C1261473
NOS	O
was	O
52	O
%	O
,	O
patients	O
with	O
localized	O
and	O
metastatic	O
disease	I:C0027627
showed	O
3	O
-	O
year	O
EFS	O
of	O
66	O
and	O
20	O
%	O
,	O
respectively	O
.	O

Three	O
-	O
year	O
EFS	O
for	O
patients	O
with	O
sarcoma	O
NOS	O
was	O
52	O
%	O
,	O
patients	O
with	O
localized	B:C0277565
and	O
metastatic	O
disease	I:C0027627
showed	O
3	O
-	O
year	O
EFS	O
of	O
66	O
and	O
20	O
%	O
,	O
respectively	O
.	O

Three	O
-	O
year	O
EFS	O
for	O
patients	O
with	O
sarcoma	O
NOS	O
was	O
52	O
%	O
,	O
patients	O
with	O
localized	O
and	O
metastatic	B:C0027627
disease	I:C0027627
showed	O
3	O
-	O
year	O
EFS	O
of	O
66	O
and	O
20	O
%	O
,	O
respectively	O
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	B:C0011900
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
EE99	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	O
than	O
metastatic	O
disease	I:C0027627
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	B:C0553580
sarcoma	I:C0553580
treated	O
according	O
to	O
EE99	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	O
than	O
metastatic	O
disease	I:C0027627
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	B:C0332154
according	O
to	O
EE99	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	O
than	O
metastatic	O
disease	I:C0027627
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
EE99	B:C1507394
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	O
than	O
metastatic	O
disease	I:C0027627
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
EE99	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	B:C0277565
than	O
metastatic	O
disease	I:C0027627
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	O
than	O
Ewing	O
sarcoma	I:C0553580
treated	O
according	O
to	O
EE99	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	O
than	O
metastatic	B:C0027627
disease	I:C0027627
.	O

Sarcomas	B:C1261473
of	O
soft	O
tissue	I:C0225317
and	O
bone	O
that	O
cannot	O
be	O
classified	O
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	O
.	O

Sarcomas	O
of	O
soft	B:C0225317
tissue	I:C0225317
and	O
bone	O
that	O
cannot	O
be	O
classified	O
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	O
.	O

Sarcomas	O
of	O
soft	O
tissue	I:C0225317
and	O
bone	B:C0391978
that	O
cannot	O
be	O
classified	O
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	O
.	O

Sarcomas	O
of	O
soft	O
tissue	I:C0225317
and	O
bone	O
that	O
cannot	O
be	O
classified	B:C0008902
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	O
.	O

Sarcomas	O
of	O
soft	O
tissue	I:C0225317
and	O
bone	O
that	O
cannot	O
be	O
classified	O
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	B:C0805586
.	O

